AstraZeneca Beats Expectations on Strong Cancer Drug Sales
AstraZeneca reported better-than-expected results, driven by robust demand for its cancer treatments. Company executives said continued investment in innovation remains a priority as competition from Chinese biotechnology companies intensifies.